Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08IFL
|
|||
| Former ID |
DAP000815
|
|||
| Drug Name |
Meclofenamic acid
|
|||
| Synonyms |
Arquel; Meclofenamate; Acide meclofenamique; Acido meclofenamico; Acidum meclofenamicum; Meclophenamic acid; CL 583; INF 4668; Acide meclofenamique [INN-French]; Acido meclofenamico [INN-Spanish]; Acidum meclofenamicum [INN-Latin]; INF-4668; Meclomen (free acid); Meclofenamic acid (USAN/INN); Meclofenamic acid [USAN:INN:BAN]; N-(2,6-Dichloro-3-methylphenyl)anthranilic acid; N-(2,6-Dichloro-m-tolyl)anthranilic acid; N-(3-Methyl-2,6-dichlorophenyl)anthranilic acid; 2-((2,6-Dichloro-3-methylphenyl)amino)benzoic acid; 2-(2,6-Dichloro-3-methylphenyl)aminobenzoic acid; 2-(2,6-dichloro-3-methylanilino)benzoic acid; 2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Ankylosing spondylitis [ICD-11: FA92.0; ICD-10: M45] | Approved | [1], [2], [3] | |
| Joint pain [ICD-11: ME82; ICD-10: M25.5] | Approved | [1], [2], [3] | ||
| Therapeutic Class |
Analgesics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H11Cl2NO2
|
|||
| Canonical SMILES |
CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl
|
|||
| InChI |
1S/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19)
|
|||
| InChIKey |
SBDNJUWAMKYJOX-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 644-62-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9328, 400193, 840128, 7457972, 7849400, 7979877, 8152527, 11335679, 11360918, 11363787, 11366349, 11368911, 11371551, 11373614, 11377073, 11461890, 11466234, 11467354, 11484706, 11485848, 11488861, 11490302, 11491853, 11494707, 14800267, 24424562, 29223148, 46507887, 47365144, 47440206, 47588953, 47662236, 47959696, 48110417, 48110418, 48334447, 49846785, 49870448, 50103859, 50264248, 53788368, 57322106, 85173910, 85788470, 85789196, 103173431, 103828114, 104305246, 117467594, 118313497
|
|||
| ChEBI ID |
CHEBI:6710
|
|||
| ADReCS Drug ID | BADD_D01363 | |||
| SuperDrug ATC ID |
M01AG04; M02AA18
|
|||
| SuperDrug CAS ID |
cas=000644622
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides fragilis enterotoxigenic
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides fragilis enterotoxigenic was decreased by Meclofenamic acid sodium salt monohydrate (adjusted p-values: 5.38E-04). | |||
|
Studied Microbe: Bacteroides fragilis nontoxigenic
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides fragilis nontoxigenic was decreased by Meclofenamic acid sodium salt monohydrate (adjusted p-values: 8.96E-03). | |||
|
Studied Microbe: Bacteroides ovatus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides ovatus was decreased by Meclofenamic acid sodium salt monohydrate (adjusted p-values: 6.17E-03). | |||
|
Studied Microbe: Parabacteroides distasonis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides distasonis was decreased by Meclofenamic acid sodium salt monohydrate (adjusted p-values: 3.02E-03). | |||
|
Studied Microbe: Parabacteroides merdae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides merdae was decreased by Meclofenamic acid sodium salt monohydrate (adjusted p-values: 8.45E-04). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostaglandin G/H synthase (COX) | Target Info | Inhibitor | [5], [6] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7219). | |||
| REF 2 | Pharmacology, pharmacokinetics, and therapeutic use of meclofenamate sodium. Clin J Pain. 1991;7 Suppl 1:S44-8. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 4 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 5 | Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7. | |||
| REF 6 | Pharmacology of prostaglandin endoperoxide synthase isozymes-1 and -2. Ann N Y Acad Sci. 1994 Apr 18;714:136-42. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.